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Summary
Background: The last decade has seen a rapid growth in the number of clinical trials
enrolling patients with nonalcoholic fatty liver disease and nonalcoholic steatohep-
atitis (NASH). Due to the underlying chronic liver disease, patients with NASH often
require different approaches to the assessment and management of suspected drug‐
induced liver injury (DILI) compared to patients with healthy livers. However, cur-
rently no regulatory guidelines or position papers systematically address best prac-
tices pertaining to DILI in NASH clinical trials.
Aims: This publication focuses on best practices concerning the detection, monitor-
ing, diagnosis and management of suspected acute DILI during clinical trials in
patients with NASH.
Methods: This is one of several papers developed by the IQ DILI Initiative, com-
prised of members from 15 pharmaceutical companies, in collaboration with DILI
experts from academia and regulatory agencies. This paper is based on extensive lit-
erature review, and discussions between industry members with expertise in drug
safety and DILI experts from outside industry to achieve consensus on common
questions related to this topic.
Results: Recommended best practices are outlined pertaining to hepatic inclusion
and exclusion criteria, monitoring of liver tests, DILI detection, approach to a sus-
pected DILI signal, causality assessment and hepatic discontinuation rules.
Conclusions: This paper provides a framework for the approach to assessment and
management of suspected acute DILI during clinical trials in patients with NASH.
The complete list of author affiliations are listed in Appendix 2.
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1 | INTRODUCTION
Nonalcoholic fatty liver disease (NAFLD) is increasingly recognized
as an important public health problem and a major cause of liver dis-
ease. Nonalcoholic steatohepatitis (NASH), a subset of NAFLD with
a higher likelihood of progression to advanced liver disease, is pre-
sently the most common cause of chronic liver disease (CLD) and a
leading indication for liver transplantation in Western countries.1–3
Over the last decade, there has been an acceleration in the search
for new therapies for NASH and the number of clinical trials enrol-
ling NASH and NAFLD patients is growing rapidly.4,5 Simultaneously,
the inclusion of patients with NAFLD/NASH into clinical trials in
therapeutic areas other than NASH is increasing and will likely con-
tinue to increase as the obesity epidemic expands worldwide. For
example, the search for new drugs for treatment of type 2 diabetes
mellitus (T2DM) has led to a myriad of clinical trials enrolling T2DM
patients that may have NAFLD in 60%‐80% of the cases.6,7 As in
other clinical trials, drug‐induced liver injury (DILI) remains a major
concern for drug developers and investigators in NASH trials. The
well‐recognized challenges in detection, assessment and manage-
ment of DILI during drug development are amplified by the fact that
a significant part of the target population may have varying degrees
of hepatic fibrosis. However, there are no regulatory guidelines and
position papers to provide information regarding DILI‐related best
practices for clinical trials enrolling patients with pre‐existing NASH.
As a result, clinical investigators and drug developers face consider-
able uncertainty when identifying and managing suspected DILI in
these trials, and often use diverse approaches and practices for
assessment and management of liver safety signals. Given the enor-
mous prevalence of CLD related to NASH worldwide, and the grow-
ing number of clinical trials assessing new drugs for NASH, there is a
great unmet need for consistent, evidence‐based recommendations
for best practices pertaining to suspected DILI in such patients.
The IQ DILI Initiative was launched in June 2016 within the
International Consortium for Innovation and Quality in Pharmaceuti-
cal Development (also known as the IQ consortium) to reach consen-
sus and propose best practices on topics related to clinical DILI.8
The IQ Consortium is a science‐focused, not‐for‐profit organisation
addressing scientific and technical aspects of drug development and
is comprised of 39 pharmaceutical and biotechnology companies.
The IQ‐DILI Initiative is an affiliate of the IQ Consortium, comprised
of 15 IQ member companies, focused on establishing best practices
for monitoring, diagnosing, managing and preventing DILI. This publi-
cation is based on an extensive literature review, and the consensus
achieved in carefully structured discussions between IQ DILI mem-
bers and academic and regulatory experts. The recommendations are
based on the opinions of the authors, and do not imply a regulatory
mandate. Although this publication focuses on DILI assessment dur-
ing drug development, post‐approval pharmacovigilance is an impor-
tant part of the safety assessment of a new drug. This is especially
important for assessment of DILI, which tends to be uncommon and
might be missed during drug development. Most of the recommen-
dations and best practices included in this publication are specific to
acute hepatocellular DILI. It is well recognized that some drugs may
cause other types of acute DILI including cholestatic liver injury,
mixed hepatocellular‐cholestatic and acute steatosis with metabolic
acidosis. It is also recognized that drugs may cause chronic liver
injury including hepatic fibrosis, steatosis, steatohepatitis, cirrhosis,
nodular regenerative hyperplasia, and vascular diseases.9 Cholestatic
DILI will be discussed in detail in another paper by the IQ DILI initia-
tive. Due to the scarcity of data in the published literature, other
types of acute DILI and chronic DILI will not be discussed in this
paper. However, it is strongly recommended that drug developers
and investigators remain mindful of these less common types of DILI
that could arise during drug development.
2 | ARE NAFLD PATIENTS SUSCEPTIBLE
TO DILI?
Whether patients with pre‐existing liver disease including NAFLD
are more susceptible to DILI compared to individuals with healthy
livers is still a matter of ongoing debate. Zimmerman was the first to
opine that most drugs could be safely given to patients with under-
lying liver disease, although he recognized that if acute injury
occurred, the outcome in such patients could be dire.10,11 Evidence
in the medical literature concerning the specific risk of DILI in
patients with NAFLD is limited and conflicting. While one study
reported that NAFLD significantly increased the risk of DILI in mid-
dle‐aged men, compared to men with hepatitis C,12 several other
reports have supported the safety of statins13–17 and of rosiglita-
zone18 in patients with NAFLD. In some of these studies, small sam-
ple sizes or significant methodologic issues limit the validity of these
observations. Furthermore, the extremely low incidence of clinically
significant statin‐related liver injury in the general population makes
it difficult to assess the specific effect of pre‐existing NAFLD.19,20
Nevertheless, based on the available evidence, there is a strong con-
sensus that statins are safe in patients with NAFLD.21 Several stud-
ies have demonstrated an association between NAFLD and
increased activity of cytochrome P450 2E1 (CYP2E1).22,23 Since
CYP2E1 plays a central role in the pathogenesis of acetaminophen‐
induced liver injury, the question of increased susceptibility of
NAFLD patients to DILI due to acetaminophen overdose has been
raised, although never examined directly. In studies of human liver
samples, steatosis was associated with decreased hepatic cyto-
chrome P450 3A (CYP3A) activity, and there appeared to be a rela-
tionship between the severity of hepatic steatosis and decreased
CYP3A activity.22,24 Hepatic CYP3A is an important subfamily of
drug‐metabolizing enzymes that contributes to drug activation and
to the control of endogenous hormone turnover; however, so far
there is no evidence to suggest an association between decreased
activity of CYP3A in NAFLD patients and DILI. Among authorities in
the field of DILI there is still a general opinion that patients with
CLD including NAFLD are not prone to develop DILI compared to
the general population.25–27 However, it is also widely believed that
patients with pre‐existing CLD are at higher risk for complicated
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course and adverse outcomes from DILI.25–28 A recent paper from
the US Drug Induced Liver Injury Network (DILIN) showed that DILI
in patients with pre‐existing liver disease was associated with signifi-
cantly higher frequency of adverse outcomes, including mortality.29
The pre‐existing CLDs were mainly hepatitis C and NAFLD or unex-
plained elevations in liver biochemistries.29
2.1 | Consensus and Recommendations
1. There is no unequivocal evidence to suggest that patients with
NAFLD/NASH are systematically predisposed to DILI. However,
if DILI occurs in a patient with advanced liver damage due to
NASH there may be an increased risk for serious liver injury and
adverse outcome.
3 | HEPATIC EXCLUSION CRITERIA FOR
PATIENTS WITH NONCIRRHOTIC NASH
Hepatic exclusion criteria depend on complex considerations and
may vary according to the indication, target patient population,
drug's mechanism of action, results of nonclinical or clinical studies,
experience with similar molecules and geographic location. From the
standpoint of liver safety, hepatic exclusion criteria aim to (a) min-
imise confusion between potential DIILI and a fluctuation or exacer-
bations of a pre‐existing liver disease; (b) decrease the risk of
adverse outcome, if DILI occurs; (c) prevent accumulation of drugs
that are eliminated by the liver. This section focuses on hepatic
exclusion criteria in clinical trials conducted in patients with NASH
who do not have apparent cirrhosis at enrolment. It should be noted
that in patients with no apparent cirrhosis some might have unde-
tected cirrhosis. Clinical trials in NASH patients with cirrhosis are
outside the scope of this paper. There is a consensus among
researchers and regulators in this field that these populations should
be studied separately,30,31 and they will be discussed in a separate
publication.
When designing a clinical trial for the treatment of patients with
NASH, drug developers generally exclude patients with pre‐existing
liver disease other than NASH, or significant abnormalities in hepatic
biochemical tests, that are outside the typical range for NASH.32–35
Several consensus papers have supported this approach in recent
years.30,31 The main rationale for excluding these patients is to
ensure a clean NASH population by avoiding a mix of different liver
diseases that may respond differently to the study drug. An addi-
tional benefit is gained through decreasing confusion between
potential DILI and a fluctuation or flare of the underlying liver dis-
ease. Most NASH clinical trials have excluded patients with viral
hepatitis B and C, or any other cause of CLD, such as haemochro-
matosis, α1 antitrypsin deficiency, autoimmune hepatitis (AIH), Wil-
son disease, primary sclerosing cholangitis or primary biliary
cholangitis.32–37 This is consistent with recommendations of consen-
sus meetings and clinical guidelines on NAFLD and NASH.30,38–41
Patients with NAFLD usually have normal or mildly elevated
serum levels of alanine aminotransferase (ALT),35,42–48 although ALT
levels of more than 300 U/L occur rarely.43 At diagnosis, ALT values
in NAFLD patients typically range between low normal values and
250 IU/L, usually lower than fivefold (5×) upper limit of normal
(ULN) (in most central laboratories, ULN for ALT is around 40‐45 U/
L). Aspartate aminotransferase (AST) values are typically lower than
ALT, but with advanced fibrosis AST may be higher than ALT.45,49,50
Total bilirubin (TBL) is usually normal until advanced stages of dis-
ease, and alkaline phosphatase (ALP) levels are usually normal,
although mild elevations (usually <2× ULN) may occur.43 Gamma
glutamyl transaminase (GGT) levels may range between low normal
and >400 U/L.33,50,51 Of note, the majority of clinical trials use the
ULN values of the central laboratory employed for the study. ULN
values for ALT and other hepatic biochemical tests may vary among
laboratories due to differences in reference populations and analyti-
cal variation among commercial assays.52 Most NASH studies have
excluded patients with ALT levels considered to be higher than the
typical range for NASH. ALT levels used as exclusion criteria vary
considerably between different NASH studies ranging from 2.5×
ULN to 300 U/L (approximately 8‐10× ULN).34,35,37,53,54 GGT level
has generally not been used as exclusion criterion. It is generally
agreed that isolated elevation of GGT is a poor indicator of liver
injury and insufficient to qualify as DILI.9,55 Several publications have
reported a high prevalence of steatohepatitis in patients infected
with human immunodeficiency virus (HIV). The mechanism for this
association is poorly understood.56–58
The extent to which workup should be performed prior to enrol-
ment to exclude other diagnoses has not been clearly defined. Based
on published clinical guidelines it has been recommended that at a
minimum, a thorough medical history should be taken, including
detailed alcohol consumption information, and serological tests for
hepatitis B, C and AIH be performed prior to enrolment. In addition,
NASH clinical trials often screen for HIV and exclude patients with
positive HIV tests.35,59,60 Other tests such as iron studies, anti‐mito-
chondrial antibody and evaluation for α1 antitrypsin deficiency or
Wilson disease, should be considered based on the nature of the
hepatic biochemical tests abnormality, the investigator's clinical
judgement, and published guidance for clinical practice.58,61
Most NASH clinical trials have excluded patients with a history of
significant alcohol use, aiming to avoid a mixed population of NASH
and alcoholic liver disease. Cut‐off levels for exclusion vary between
trials and have included 14‐21 standard drinks per week for men and
7‐14 standard drinks per week for women.33–35,47,62–,64 A standard
drink contains roughly 14 g of pure alcohol, which is equivalent to a
12‐ounce beer, a 4‐ounce glass of wine or a 1‐ounce shot of hard
liquor. It should be noted that the National Institute on Alcohol
Abuse and Alcoholism (NIAAA) defines heavy or at‐risk drinking as
more than four standard drinks on any day or more than 14 drinks
per week in men or more than three drinks on any day or seven
drinks per week in women.65 There is insufficient evidence to sup-
port the notion that patients who consume excessive alcohol are
prone to develop DILI, but it is well established that patients who
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consume large quantities of alcohol are more likely to develop alco-
holic liver disease, which may be difficult to differentiate from DILI.25
Most clinical trials in noncirrhotic NASH have also excluded
patients with cirrhosis or evidence of decreased synthetic function
(eg elevated TBL or INR), predominantly due to the differences in
study objectives and clinical benefit endpoints.32,33,35,47,63,64,66 How-
ever, depending on the study drug and its mechanism of action,
recently initiated clinical trials and future studies may strive to enrol
patients with cirrhosis to allow assessment of the drug in this patient
population. A recent consensus paper provides guidance regarding
the inclusion of patients with NASH who have advanced disease or
cirrhosis, especially in trials for therapeutics directed against fibro-
sis.31 This target population may need extensive evaluation to rule
out other aetiologies, as typical histologic features pertaining to
NASH (including steatosis) may be less prominent or absent.67 Most
clinical trials in noncirrhotic NASH have excluded patients with clini-
cal evidence of hepatic decompensation or portal hypertension
including decreased serum albumin (eg less than 32 g/L) increased
INR (eg greater than 1.2 or 1.3), elevated direct bilirubin (eg direct
bilirubin greater than 1.3 mg/dL, TBL higher than 1‐1.2× ULN), low
platelet count (<150 000/μL) or a history of oesophageal varices,
ascites or hepatic encephalopathy.35,60,61 These exclusion criteria are
in keeping with recommendations by a 2012 workshop on assess-
ment and management of DILI during drug development.55 Finally,
most NASH studies excluded patients who were receiving drugs
known to cause steatosis or steatohepatitis such as tamoxifen, amio-
darone, methotrexate, 5‐fluorouracil and corticosteroids, for more
than 2 weeks in the year prior to enrolment.32,35,47,68
3.1 | Consensus and Recommendations
2. Clinical trials in patients with NASH should aim to exclude
patients who have other acute or chronic liver diseases, to avoid
confusion regarding response to the investigational drug, and to
decrease uncertainty regarding diagnosis of DILI when abnormali-
ties of liver blood tests occur.
3. The extent of workup prior to enrolment to exclude other causes
of chronic liver disease is not clearly defined. At a minimum, a
thorough medical history, physical examination and serological
testing for hepatitis B, C, HIV and AIH should be performed.
Other tests (eg for haemochromatosis, α1 antitrypsin deficiency,
Wilson disease) should be based on the patient's history, physical
examination, laboratory results and clinical judgement.
4. It is recommended to exclude patients with evidence of active
hepatitis B virus or hepatitis C virus infection.
5. HIV infected patients should generally be excluded and need to
be studied separately.
6. Patients, who consume excessive amounts of alcohol, should be
excluded. The cut‐off for exclusion is not yet well defined but
should not exceed 21 standard drinks per week in men and 14
standard drinks per week in women over a 2‐year period prior to
enrolment.
7. Patients with baseline ALT or AST higher than 5× ULN or 250 U/
L, should be excluded.
8. Patients with elevated baseline levels of total bilirubin (higher
than 1.2× ULN, or 1.3 mg/dL, (with exception of Gilbert's syn-
drome), with INR >1.2, or platelet count below the lower limit of
normal (typically <150 000/μL), should generally be excluded.
This recommendation does not apply to studies aiming to enrol
patients with hepatic decompensation.
9. Patients with elevated ALP, equal to or higher than 2× ULN or
250 U/L, should generally be excluded, unless the ALP elevation
is not from a hepatic origin.
4 | MONITORING OF LIVER TESTS AND
DILI DETECTION IN NASH CLINICAL TRIALS
As aminotransferases (ATs) (ALT and AST) often fluctuate as part of
the natural course of the disease, detection of DILI signals during a
clinical trial may be challenging in patients with NASH.38,46 While
the degree of fluctuation of ATs during the natural history of NASH
has not been clearly defined, the published data indicate that they
typically do not fluctuate more than 1.5‐2× baseline values.35,47,49,63
Furthermore, baseline AT levels may decrease in response to therapy
or lifestyle modification, which may create a new reference baseline
for ALT changes during the study.33,35,47,63 According to current reg-
ulatory guidance for patients participating in a clinical trial, who have
no underlying liver disease and normal baseline ALT, treatment
emergent ALT values exceeding 3× ULN should trigger close obser-
vation and workup for likely causes of hepatic injury other than the
study drug.69 In 2011, an international DILI Expert Working Group
suggested that in the absence of liver‐related symptoms or elevated
TBL, a cut‐off value of ALT >5× ULN would be a more appropriate
threshold for a DILI signal. The main rationale for this proposal was
that raising the cut‐off level to 5× ULN is more likely to exclude clin-
ically insignificant and/or self‐limited drug related events, as well as
AT fluctuations that normally occur in NASH and do not indicate a
DILI signal.9 Many drug developers have adopted this threshold for
studies enrolling patients with healthy livers; however, it may not be
suitable for patients with NASH, who may have baseline ALT levels
exceeding 3×ULN. Under these circumstances, it has been suggested
to use multiples of baseline of ALT rather than multiples of ULN as
a threshold for suspecting DILI.9,30,69,70
The Food and Drug Administration (FDA) has recommended
using ALT threshold values of >2× baseline in patients with elevated
ATs at enrolment,69 however, others have suggested an increase of
>3× baseline and >5× baseline as more appropriate for hepatic
safety signal detection.9,30 In the absence of large prospective com-
parative data, there is little evidence to support one suggested
threshold over another. Recently, a combination of these approaches
has been proposed as a more useful alternative70 (Table 1). The
actual cut‐off values may need to be adjusted based on nonclinical
data, mechanism of action or hepatic safety signals in early‐phase tri-
als. Finally, when designing liver‐related monitoring and stopping
REGEV ET AL. | 705
criteria it is important to take into consideration the degree of varia-
tion that exists for ALT reference ranges between laboratories,
where ULN values may vary between less than 30 U/L for some lab-
oratories to more than 70 U/L for others.71,72
How to determine baseline ALT is also a matter of debate. Since
in patients with NASH, ALT levels can fluctuate even over a short
period, a single measurement on a given day may not represent a true
baseline. It has been suggested to take at least two ALT measure-
ments prior to enrolment (at least 2 weeks apart) and use the average
of the two values as the most appropriate baseline.55,70 These mea-
surements can be performed at the “screening visit” (typically visit 1)
and the “baseline visit” (typically visit 2 or 3). In cases of significant
changes between two measurements (for example, >50% difference),
it has been suggested to obtain a third measurement for a better esti-
mate of the magnitude and trend of the ALT changes.70 If a patient
exhibits a sharp change prior to enrolment, it would be preferable to
hold enrolment until the underlying cause is identified or ALT levels
stabilize. This approach may be time consuming and may not be feasi-
ble for all clinical trials. To harmonise and simplify the definition of
“elevated baseline ALT” some authors have recommended to use ALT
>1.5× ULN as an empiric threshold (see Table 1).70
As demonstrated in several studies, AT levels may decrease dur-
ing the treatment period in response to NASH treatment or life
style modifications.33,35,47,63 However, in contrast to certain other
liver diseases (eg AIH, chronic hepatitis C), in which the ALT decline
in response to therapy often results in a new nadir, the decrease in
ALT in NASH is typically not as abrupt or substantial. Changes from
baseline in response to therapy have been reported in clinical trials
to range between 12 and 20 U/L for ALT, 5‐10 IU/L for AST and 5‐
14 U/L for GGT.33,35,47,63 However, in some instances, response to
therapy in NASH patients may lead to more substantial improve-
ment in liver enzymes.33,73 For studies in hepatitis C, several
authors have suggested that ALT baseline should be adjusted
according to the nadir attained during treatment.70,71,74 The IQ DILI
working group recommended that a similar approach may be advis-
able in patients with NASH who experience a significant improve-
ment in ALT level (eg a decrease of >50% of the original ALT
baseline to a new stable level during the trial). For example, in a
patient with a baseline ALT of 200 U/L, who experienced a decrease
in ALT to a stable level of 100 U/L, future elevations of ALT should
be viewed and managed as a change from the new ALT baseline of
100 U/L.
TABLE 1 Algorithm for monitoring and management of possible hepatocellular DILI in phase 2‐3 NASH clinical trials in patients with normal
or elevated baseline ALTa
Treatment emergent ALT
Treatment emergent total
bilirubin
Liver‐related
symptoms Actionb
Normal/near normal baselinea:
ALT ≥5× ULN
Elevated baselinea:
ALT ≥3× baseline or ≥300 U/L
(whichever occurs first)
Normal
Patients with Gilbert's
syndrome:
No change in baseline TBL
None Repeat ALT, AST, ALP, TBL, in 2‐5 d. Follow‐up for
symptoms. Initiate evaluation for other etiologies of
abnormal liver tests.
Normal/near normal baselinea:
ALT ≥3× ULN
Elevated baselinea:
ALT ≥2× baseline or ≥300 U/L
(whichever occurs first)
Normal
Patients with Gilbert's
syndrome:
No change in baseline TBL
Severe fatigue, nausea,
vomiting, right upper
quadrant pain
Repeat ALT, AST, ALP, TBL, in 2‐5 d. Follow‐up for
symptoms. Initiate evaluation for other etiologies of
abnormal liver tests.
Normal/near normal baselinea:
ALT ≥8× ULN
Elevated baselinea:
ALT ≥5× baseline or ≥500 U/L
(whichever occurs first)
Normal
Patients with Gilbert's
syndrome:
No change in baseline TBL
None Interrupt study drug. Initiate close monitoring and
workup for competing etiologies. Study drug can be
restarted only if another aetiology is identified and
liver enzymes return to baseline.
Normal/near normal baselinea:
ALT ≥3 ULN
Elevated baselinea:
ALT ≥2× baseline or ≥300 U/L
(whichever occurs first)
TBL ≥2× ULN
Patients with Gilbert's
syndrome:
Doubling of direct bilirubin or
increased INR to >1.5
None Interrupt study drug. Initiate close monitoring and
workup for competing etiologies. Study drug can be
restarted only if another aetiology is identified and
liver enzymes return to baseline.
Normal/near normal baselinea:“
ALT ≥5 ULN
Elevated baselinea:
ALT ≥3× baseline or ≥300 U/L
(whichever occurs first)
Normal or elevated Severe fatigue, nausea,
vomiting, right upper
quadrant pain
Interrupt study drug. Initiate close monitoring and
workup for competing etiologies. Study drug can be
restarted only if another aetiology is identified and
liver enzymes return to baseline.
ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; INR, international normalized ratio; TBL, total bilirubin, ULN,
upper limit of normal.
Modified from Chalasani and Regev.70
aBaseline ALT is derived from an average of two pre‐treatment ALT measurements at least 2 weeks apart. Elevated baseline is defined as ALT ≥1.5×
ULN. In patients with a sizable stable decrease in ALT (>50% of the baseline value) during treatment, a new baseline, corresponding to the ALT nadir,
should be established on an individual basis for subsequent determination of a DILI signal.
bThe actions of close observation, monitoring, and drug interruption often overlap. Occasionally, workup is initiated after drug interruption.
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4.1 | Consensus and Recommendations
10. In patients with NASH who have normal or near normal base-
line ALT (ie ALT <1.5× ULN), ALT elevation of ≥5× ULN in the
absence of hepatic symptoms (such as severe fatigue, abdominal
pain, nausea or vomiting) or elevated TBL, is a reasonable
threshold to suspect DILI and to initiate close observation and
monitoring (Table 1).
11. In patients with normal or near normal baseline ALT, a combina-
tion of ALT ≥3×ULN plus TBL ≥2×ULN* or ALT ≥3×ULN plus
hepatic symptoms should be considered as a signal of potential
DILI (Table 1).
12. In patients with elevated baseline ALT (≥1.5×ULN), ALT eleva-
tion of >3× baseline or greater than 300 U/L (whichever comes
first), even in the absence of hepatic symptoms or elevated
TBL, is a reasonable threshold to suspect DILI and to initiate
close observation and monitoring (Table 1). The threshold val-
ues may need to be adjusted based on nonclinical data, mecha-
nism of action or hepatic safety signals in early‐phase trials.
13. In patients with elevated baseline ALT (≥1.5× ULN), a combina-
tion of ALT ≥2× baseline or ALT ≥300×ULN (whichever comes
first) plus TBL ≥2×ULN* or hepatic symptoms, should be con-
sidered as a signal of potential DILI and require interruption of
the study drug (Table 1).
14. In patients who meet the criteria for a DILI signal, assessment
for hepatic symptoms and liver tests should be repeated within
2‐5 days. The specific interval between the tests should be
determined based on the patient's clinical condition.
15. Baseline values of ALT may need to be established based on an
average of two consecutive tests performed at least 2 weeks
apart prior to enrolment (preferably during the screening and
baseline visits). If there is change in ALT level of >50% between
the two tests, it may be prudent to perform a third test to
determine the direction of the change, and to avoid enrolment
until the cause is identified and ALT level stabilizes.
16. In patients with a sizable stable decrease in ALT level during
treatment (>50% of the baseline value), a new baseline, corre-
sponding to the ALT nadir, may need to be established for sub-
sequent determination of a DILI signal.
17. When designing liver‐related monitoring and stopping rules, it is
important to take into consideration the variation of normal
ALT range that exists among laboratories.
(*Does not apply to patients with Gilbert's syndrome.)
5 | SPECIAL CONSIDERATIONS FOR
CAUSALITY ASSESSMENT OF SUSPECTED
DILI IN PATIENTS WITH NASH
Causality assessment for suspected DILI is usually challenging during
drug development, in part because there is insufficient information
on the hepatic safety profile of the drug, and it is often unknown
whether a study subject is receiving the active drug or placebo.75,76
The difficulty increases when study subjects have pre‐existing liver
disease such as NASH, which may lead to fluctuation in hepatic bio-
chemical tests.9 Causality assessment is required in NASH patients
who meet the criteria for suspected DILI during a clinical trial
(Table 1). A comprehensive discussion of the various methods of
causality assessment is beyond the scope of this paper; however,
several considerations, which are unique to drug development for
NASH, are outlined. Patients with NASH are usually asymptomatic
or report mild nonspecific symptoms such as fatigue or right upper
abdominal discomfort.42 Therefore, new or worsening symptoms
such as abdominal pain, severe fatigue, nausea or vomiting should
raise suspicion of other diagnoses (including DILI). Changes in liver
tests due to underlying NASH usually are hepatocellular in nature,
and most NASH patients have normal to moderately elevated ALT
levels. While the magnitude of “normal” fluctuation in ALT level in
NAFLD/NASH is not well defined, ALT elevation of ≥5× ULN is rare,
and usually should not be attributed to NASH during a clinical trial,
especially if this elevation represents a significant change from the
patient's baseline. In such patients, investigators should consider
other causes such as viral hepatitis A‐E, AIH, gallstone disease or
DILI. Thorough history of concomitant medications, alcohol con-
sumption and dietary and nutritional supplements is essential. Eleva-
tion of ALP or TBL to ≥2× ULN is also atypical of NASH and other
causes (such as gallstone disease, hepatic tumour, pancreatic tumour
or DILI) should be thoroughly investigated.77,78 Concomitant eleva-
tion of ALT and ALP increases the likelihood that the cause is DILI,
which may be mixed, hepatocellular and cholestatic.77,78 According
to a few publications, a small subset of NASH patients (predomi-
nantly women) may have isolated elevation in ALP (typically less
than 2× ULN) instead of the more typical AT elevations.77,78 The
clinical significance of this observation is not well understood and
requires further study.
Patients with long‐standing T2DM and other features of the
metabolic syndrome have a higher risk of cholelithiasis, pancreatic
carcinoma, cholangiocarcinoma and hepatocellular carcinoma com-
pared to nondiabetic populations.79,80 Furthermore, patients with
NASH often are started on low calorie diets as part of their treat-
ment, which may further raise the risk of cholelithiasis, largely due
to increased cholesterol flux through the biliary system.81 Patients
undergoing rapid weight loss from dieting or gastric surgery are at
particularly increased risk of gallstones and their complications. Pas-
sage of a gallstone or choledocholithiasis may closely resemble cho-
lestatic DILI and occasionally acute hepatocellular DILI. Therefore,
the assessment of a NASH patient with a treatment emergent
abnormality in hepatic biochemical tests should take into account
the possibility of gallstone‐related disease. Importantly, intensive
exercising (eg weight lifting), started in conjunction with other life-
style changes for NASH can lead to an acute elevation in AST and
ALT due to muscle injury, that can be mistaken for acute DILI.
Patients receiving statins as concomitant therapy for dyslipidemia,
may also have elevated ALT and AST due to statin‐related muscle
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injury. Testing for blood levels of creatine phosphokinase (CK), aldo-
lase or other muscle‐related enzymes can confirm the nonhepatic
origin of this event.
Anti‐nuclear antibodies (ANA) and anti‐smooth muscle antibodies
(ASMA) are frequently positive with low titres in NASH patients and
are generally considered an epiphenomenon of no clinical conse-
quence.58,82 In an analysis from the NASH Clinical Research Net-
work (NASH CRN), elevated serum autoantibodies levels (ANA
≥1:160 or ASMA ≥1:40 or both) were present in 21% of 864
patients with biopsy‐proven NAFLD, in the absence of AIH.82 The
finding of positive titres for ANA or ASMA may be confusing and is
unhelpful for causality assessment of a potential DILI in patients
with NASH. A liver biopsy may be helpful in ruling out idiopathic
AIH, especially in patients with concomitant hypergammaglobuline-
mia or other clinical features suggesting AIH.58,75,83 Another poten-
tially confounding biochemical finding in patients with NASH is an
elevated serum ferritin level, however, iron overload disorders do
not generally cause acute liver injury and therefore evaluation for
iron overload is normally not necessary in a NASH patient with
acute hepatocellular injury during a clinical trial.84,85
As in other circumstances of suspected DILI, a liver biopsy is
usually not required for causality assessment, but when performed,
it can provide important and useful information on the pattern of
injury and its severity. A liver biopsy may be particularly helpful in
the setting of pre‐existing NASH and an experimental agent in early
development for which there is little prior information regarding liver
injury. It may also be useful when there are multiple candidates as
the causal agent, and for exclusion of AIH.86
5.1 | Consensus and Recommendations
18. In NASH patients with normal or near normal baseline ALT, an
increase of ALT to ≥5× ULN during a clinical trial should not be
presumed due to underlying NASH, but should trigger an evalu-
ation for an alternative aetiology including possible DILI. Simi-
larly, the occurrence of ALT elevation >3×ULN with new onset
or worsening hepatic symptoms (severe fatigue, abdominal pain,
nausea, or vomiting) should prompt an evaluation for alternative
aetiology (as well as interruption of the study drug).
19. In NASH patients with elevated baseline ALT (≥1.5× ULN), an
increase of ALT to ≥3× baseline, or ≥300 U/L (whichever comes
first) during a clinical trial should not be presumed due to
underlying NASH, and should prompt an evaluation for alterna-
tive aetiologies including possible DILI.
20. Elevated serum autoantibodies titres (ANA >1:160 or ASMA
>1:40) may be encountered in NAFLD patients, and do not nec-
essarily suggest AIH. The finding of autoantibody positivity
associated with hypergammaglobulinemia should prompt further
evaluation including consideration of a liver biopsy.
21. It is recommended to measure autoantibody titres (ANA and
ASMA) prior to enrolment, to provide a baseline for subsequent
comparison.
22. Elevated ferritin levels may be encountered in patients with
NAFLD. This finding should not automatically prompt evaluation
for iron overload unless associated with an elevated transferrin
saturation.
23. Emergence of ALP ≥2×ULN is not typical of NASH and should
prompt an evaluation for alternative aetiology including DILI.
6 | ASSESSMENT OF DILI RISK DURING
DRUG DEVELOPMENT IN PATIENTS WITH
NASH
Assessment of a candidate drug's potential to cause severe DILI
relies predominantly on changes in routine hepatic biochemical tests
(ALT, ALP, TBL and INR) during clinical phases of drug develop-
ment.9,28,69 An imbalance (even as low as 1.2%) in the frequency of
ALT elevation >3× ULN between active treatment and placebo/com-
parator during clinical development may sometimes be the first sig-
nal of a high risk of severe DILI post‐marketing, although such
imbalance may also appear in studies of drugs that have proven to
be safe to the liver (for example, statins).69,75,87 In addition, a small
imbalance of ALT ≥3× ULN may become insignificant when the
study population includes a relatively high percentage (eg >20%) of
patients with ALT >3×ULN prior to enrolment. Since this may be
the case in clinical trials enrolling NASH patients, it has been recom-
mended to adjust the approach to DILI risk assessment in such clini-
cal trials.30,70 In patients enrolled with elevated ALT (ie ALT >1.5×
ULN), searching for an imbalance in ALT >5× ULN or multiple of
baseline ALT between the drug and comparator has been proposed
as more informative.9,70
Hy's law is currently the most specific tool available to the phar-
maceutical industry and regulatory agencies for assessing a drug's
potential to cause severe hepatocellular DILI.10,11 Its predictive value
has been validated in DILI registries from Sweden,88 Spain89 and the
US,90 where the risk of death or need for liver transplantation from
acute DILI causing jaundice, approximates 10%.10,11
The current definition of Hy's law10,11 was intended to be
applied in patients without underlying liver disease and thus presents
a significant challenge when dealing with patients with NASH.
According to current guidelines, a Hy's law case is defined by (a)
ALT elevation ≥3× ULN; (b) TBL ≥2× ULN; (c) absences of signifi-
cant cholestasis; and (d) no other cause explaining the elevation of
ALT and TBL. In addition, the suspected drug should show a higher
incidence of ALT >3× ULN compared to the control drug or pla-
cebo.69 Yet, in studies enrolling patients with NASH, ALT elevation
may be related to the underlying NASH and thus the test abnormali-
ties may not meet the definition of Hy's law. As a result, the predic-
tive value of Hy's law, based on its current definition, may be
diminished. Nevertheless, it is widely agreed that the underlying con-
cept of Hy's law remains valid, although the biochemical criteria may
need to be modified. The optimal approach to using Hy's law in clini-
cal trials in patients with NASH is still a matter of debate and clear
guidelines and definitions are lacking. A few groups have suggested
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improved predictive models based on modified definitions of Hy's
law, however, these modified definitions have not been assessed for
drug development or in a clinical trial setting in patients with ele-
vated baseline liver tests, and will require further assessment and
validation.91,92
The Evaluation of Drug‐Induced Serious Hepatotoxicity (eDISH)
plot, another widely used hepatic safety assessment tool by regula-
tors and drug developers, allows scanning of large numbers of clini-
cal trial patients for indicators of hepatocellular injury by serum ALT
and TBL levels. However, eDISH was originally designed for patients
who are enrolled into clinical trials with no underlying liver dis-
ease.28,93 The right upper quadrant of the eDISH plot, referred to as
“Hy's law range,” includes all study subjects with ALT >3× ULN and
TBL >2× ULN. This quadrant identifies patients of special interest
for which more clinical information should be sought for medical
diagnosis of the most likely cause. These patients may potentially
represent Hy's law cases, if there is no significant cholestatic abnor-
mality, and the liver injury is caused by the study drug.28,93 While
eDISH is still useful and effective in NASH clinical trials, it is more
likely that patients in the Hy's law range may have had abnormal
liver tests at baseline, and careful assessment of these patients is
needed. There is an ongoing discussion on the best way to use the
eDISH plot in patients enrolled in clinical trials with pre‐existing CLD
such as NASH. It is possible that future modification using different
cut‐off values may improve the use of eDISH in this patient popula-
tion.
6.1 | Consensus and Recommendations
24. When peak levels of ALT ≥3× ULN and TBL ≥2× ULN are
observed in a NASH patient enrolled in a clinical trial, the bio-
chemical threshold levels of acute hepatocellular injury consis-
tent with Hy's law may not be met, because of prior ALT
elevation at baseline.
25. Recently suggested modified biochemical threshold criteria for
Hy's law have not been assessed for drug development and
require further assessment and validation for patients with
underlying liver disease such as NASH.
26. eDISH remains useful in NASH clinical trials, however, patients
in the Hy's law quadrant need careful assessment based on
their baseline ALT and TBL values.
27. Presently, there is no evidence to support that existing modifi-
cations to eDISH are advantageous for clinical trials in patients
with NASH.
7 | HEPATIC DISCONTINUATION RULES
In most idiosyncratic DILI cases, the only effective treatment is dis-
continuation of the causal agent. Delayed discontinuation can result
in irreversible liver failure and death.10,90 On the other hand, auto-
matic discontinuation of a study drug upon finding a mild
abnormality in liver enzymes (eg elevation of ALT or AST to >3×
ULN without hepatic symptoms or elevated TBL) is usually unneces-
sary and may make it difficult to differentiate between a drug that is
associated with benign self‐limiting AT elevations and a drug that
may cause clinically significant liver injury.28,69 Current regulatory
recommendations regarding hepatic discontinuation rules focus on
patients who are enrolled in clinical trials with healthy livers and nor-
mal hepatic biochemical tests.69,94 According to the US FDA guideli-
nes, discontinuation of the study drug should be considered in any
one of the following conditions: (a) ALT or AST ≥8× ULN; (b) ALT or
AST ≥5× ULN for more than 2 weeks; (3) ALT or AST ≥3× ULN
with TBL ≥2× ULN or INR>1.5; (4) ALT or AST ≥3× ULN with
symptoms such as fatigue, nausea, vomiting, right upper quadrant
pain or tenderness, fever, or rash.69 However, in some patients with
NASH, ALT and AST may approach or cross these levels at baseline
or during the trial, which may lead to premature discontinuations if
these same stopping rules are applied.32–35 Several experts have sug-
gested that in patients with NASH enrolled in clinical trials with ele-
vated ALT, AST or TBL, discontinuation rules should be determined
as multiples of baseline rather than multiples of ULN.30,70 For exam-
ple, it has been suggested that in patients with NASH enrolled with
elevated ALT discontinuation should be considered for ALT levels
exceeding 5× baseline or 500 U/L (whichever occurs first) (Table 1).
Concurrent elevation of ALT and TBL should be viewed as a more
specific indication of severe DILI and should lead to an earlier dis-
continuation. In such cases, patients who had normal TBL and ALT
of ≥1.5× ULN at baseline, may need to be considered for discontin-
uation when ALT is ≥2× baseline, if TBL increases to ≥2× ULN
(Table 1). Of note: Occasionally in clinical trials the study drug has to
be interrupted, but can then be resumed when a clear cause of liver
injury other than the drug is identified and liver enzymes improve.
7.1 | Consensus and Recommendations
28. When considering study drug discontinuation in NASH patients
with suspected DILI, who had elevated baseline ALT
(≥1.5×ULN), it is recommended to assess the change from base-
line rather than the change from ULN (Table 1).
29. In patients with normal baseline ALT and TBL, study drug dis-
continuation should conform to the current FDA stopping rules:
(a) ALT ≥8×ULN, (b) ALT ≥3× ULN and TBL ≥2× ULN or
INR>1.5, (c) ALT ≥3× ULN and symptoms such as severe fati-
gue, fever, right upper quadrant pain, nausea, or vomiting.
30. In patients with elevated baseline ALT (ALT >1.5× ULN) study
drug discontinuation should be considered if one of the follow-
ing occurs: (a) ALT ≥5× baseline or ≥500 U/L (whichever occurs
first), (b) ALT ≥2× baseline or ≥300 U/L (whichever occurs first)
and TBL ≥2× ULN, (c) ALT ≥2× baseline or ≥300 U/L (which-
ever occurs first) and symptoms such as severe fatigue, fever,
right upper quadrant pain, nausea, or vomiting.
31. When ALT and AST have improved considerably during treat-
ment (eg a reduction of >50% of the baseline values), the new
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nadir should be considered as the new baseline for monitoring
and discontinuation decisions.
32. Occasionally, the study drug has to be interrupted because of
acute biochemical changes, but can then be resumed when a
clear cause other than the drug is identified, and liver enzymes
improve.
8 | BIOMARKERS FOR DETECTION AND
ASSESSMENT OF DILI IN PATIENTS WITH
NASH
Despite intensive efforts to identify and develop new noninvasive
biomarkers for detection and assessment of DILI, none of these
future biomarkers is qualified or ready for routine use. Ongoing
efforts are being spearheaded by groups such as TransBioline (under
the Innovative Medicines Initiative), Predictive Safety Testing Consor-
tium (under the Critical Path Institute), DILIN, and others. A detailed
discussion of these biomarkers is outside the scope of this article.
9 | MONITORING AND ASSESSMENT OF
DILI IN CIRRHOTIC NASH PATIENTS WITH
OR WITHOUT HEPATIC DECOMPENSATION
While a complete discussion of the assessment and management of
DILI occurring in patients with cirrhotic NASH is beyond the scope
of this paper, a few points will be briefly addressed. Monitoring and
assessment of DILI in patients with cirrhosis present drug developers
and clinical investigators with unique challenges, which to date have
not been addressed in existing regulatory guidance. It should be
noted that patients with advanced liver disease can have normal AT
values or only mild elevations. Importantly, the AST:ALT ratio may
increase to >1 in such patients, and the ratio may increase as the dis-
ease progresses.95 In general, DILI in patients with preexisting liver
dysfunction may sometimes present with rapid deterioration of liver
function (ie elevated direct bilirubin and prolonged INR), with only
mild changes in ATs.96–98 Therefore, close monitoring is essential in
such patients, to enable early detection of the first signs of DILI, and
ensure early discontinuation of the drug. Such patients are often
highly confounded and causality assessment may be very challenging.
To date there are no published systematic reports of drug treatment
in patients with NASH‐related advanced liver disease or decompen-
sated cirrhosis, although clinical trials are ongoing. In fact, relatively
few publications discuss the management of DILI patients with pre-
existing liver dysfunction who participate in clinical trials.55,70
10 | SUMMARY
The number of drug‐development programs for NASH has grown
considerably over the last decade. Moreover, the inclusion of
patients with diagnosed or undiagnosed NASH into trials in other
therapeutic areas is increasing rapidly, and will likely continue to
increase as the obesity and diabetes epidemic expands worldwide.
There is a great need for consistent and evidence based recommen-
dations for best practices to enable better monitoring, assessment,
and management of suspected DILI in patients with NASH. This
paper provides a framework for recommendations based on the col-
laborative work of the IQ DILI initiative with experts from academia
and other experts in the DILI field.
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